Literature DB >> 165828

An examination of octanol and octanal metabolism to octanoic acid by horse liver alcohol dehydrogenase.

J A Hinson, R A Neal.   

Abstract

The kinetics of the horse liver alcohol dehydrogenase (alcohol: NAD+ oxidoreductase EC 1.1.1.1) catalyzed metabolism of octanol and octanal to octanoic acid have been examined. On incubation of octanol with horse liver alcohol dehydrogenase in the presence of NAD+, NADH as well as octanal and octanoic acid were seen as the initial products. However, on continued incubation, the octanal concentration progressively decreased to where only negligible quantities were present in the incubation after 10 min. The production of NADH was biphasic. An initial phase was followed in about 2 min with a slower but linear rate of NADH production. The production of octanoic acid was approximately linear throughout the 10 min incubation period. Since octanal is an intermediate in the oxidation of octanol to octanoic acid, the ability of semicarbazide to inhibit the metabolism of octanol to octanoic acid was examined. At a concentration of semicarbazide which was 63 times the concentration of octanol in the incubation media, the rate of formation of octanoic acid was inhibited by only 30%. The results of these experiments suggest that in the oxidation of octanol to octanoic acid a portion of the octanal formed from octanol is not released from the enzyme but, in the presence of NAD+, is oxidized to octanoic acid.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 165828     DOI: 10.1016/0005-2744(75)90090-x

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  1 in total

1.  An open-label, single-dose, crossover study of the pharmacokinetics and metabolism of two oral formulations of 1-octanol in patients with essential tremor.

Authors:  Fatta B Nahab; Loretta Wittevrongel; Dominic Ippolito; Camilo Toro; George J Grimes; Judith Starling; Gopal Potti; Dietrich Haubenberger; Daniel Bowen; Peter Buchwald; Chuanhui Dong; Daniel Kalowitz; Mark Hallett
Journal:  Neurotherapeutics       Date:  2011-10       Impact factor: 7.620

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.